New Drug Combination for High-Risk Neuroblastoma
Researchers create novel combination as potential therapy for high-risk neuroblastoma. This combination is made of epigenetic inhibitors and B-cell lymphoma 2 (BCL-2) inhibitors. BCL-2 inhibitors are already approved by the U.S. Food and Drug Administration.
Read More
